#For patients

Written for adults considering a peptide as part of their health management.

About 40% of GLP-1 orders are never dispensed. Here is what the fill-rate evidence on semaglutide and tirzepatide shows, and what it cannot show.

GLP-1 medicines such as semaglutide are not approved to treat PCOS, and current labels require stopping the drug before a planned pregnancy.

A US claims study of 22,512 tirzepatide starters found 68% still on the drug at six months. Here is what that number does and does not tell you.

A reader on r/peptides asked if peptides could fix years of unexplained weight gain. Here is what GLP-1 drugs actually do, and what to test first.

A matched cohort study links semaglutide and liraglutide use to higher ulcerative colitis remission, though neither drug is approved for IBD.

Retatrutide is investigational, and even FDA-approved GLP-1 pens must be discarded weeks after first use, not months later.

A reddit user's heart rate spiked to 151 bpm after combining tesamorelin, ipamorelin and TRT. Here is what the evidence on each actually shows.

A 2026 case report describes a chest rash clearing during tirzepatide-associated weight loss. Here is what one patient shows, and does not.

A 2026 case report describes tirzepatide easing treatment-resistant diabetes in an adult with Prader-Willi syndrome. Here is what one patient shows.

BPC-157 and TB-500, the 'wolverine stack,' carry risks from unverified sourcing and peer-relayed dosing on top of thin human evidence.

A new meta-analysis links GLP-1 drugs like semaglutide and tirzepatide to modest erectile-function gains, though other research disagrees.

A new JEADV letter examines whether GLP-1 and GLP-1/GIP drugs like tirzepatide and semaglutide change healthcare use in psoriasis patients.